Life Sciences Voice

Nominations now open for inclusion in the Prestigious list of Rising Stars in the Life Sciences Industry. Nominate Now: https://lnkd.in/dBMwvHea #RisingStars #awards2024 #Awards #risingstarsaward #nominations #lifesciences #lifescivoice

Vertex and CRISPR Therapeutics are making headway on the difficult path to assuring the availability of gene therapy Casgevy in the U.K. They have received a thumbs-up from England’s National Institute for Health and Care Excellence (NICE) for one of...

Pfizer reported top-line interim safety and immunogenicity outcomes from Substudy B within the MONeT-RSV Immunization Study for Adults, showing that two doses of the ABRYSVO vaccine provided safety and immunogenicity in immunocompromised individuals...

Kidney disease biotech Pathalys Pharma has raised $105 million in a Series B funding round, which the company will use to advance its lead product to the final stages of clinical trials. The company’s primary candidate, upacicalcet, is a calcimimetic...

Eli Lilly’s weight loss drug, tirzepatide, has shown a 94% reduction in the incidence of Type 2 diabetes among obese or overweight adults with prediabetes, according to a recent clinical trial. This latest phase of the trial revealed that tirzepatide,...

Eli Lilly and Company’s weight loss drug, tirzepatide, has shown a 94% reduction in the incidence of Type 2 diabetes among obese or overweight adults with prediabetes, according to a recent clinical trial. #elililly #clinicaltrial #lifesciences

Kidney disease biotech Pathalys Pharma has raised $105 million in a Series B funding round, which the company will use to advance its lead product to the final stages of clinical trials. #biotech #pharma #clinicaltrials #lifessciences

American-based specialty pharmaceutical company Mallinckrodt has undertaken the divestment of the photopheresis segment, Therakos, to global private equity firm CVC Capital Partners for $925 million. Mallinckrodt, which produces both branded and...

Humana Settles Whistleblower Suit for $90 Million Humana has reached an agreement to pay $90 million in order to resolve a False Claims Act action that it has been involved in concerning its Medicare Part D contracts. #Humana #whistleblower #medicare #LifeSciences

Novartis Hits Roadblock in Preventing MSN’s Entresto Generic Launch #Novartis #MSN #Generic #healthcare #LifeSciences